Outcomes of a standardized triple-drug regimen for the treatment of nontuberculous mycobacterial pulmonary infection.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 18532890.
- Also identified by DOI 10.1086/589250.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The treatment of fibrocavitatory pulmonary infection due to Mycobacterium avium complex and Mycobacterium malmoense poses a challenge. This study assessed microbial, inflammatory, radiographic, and clinical outcomes for a standardized 24-month triple-drug regime. Following treatment completion, all patients had fewer symptoms, experienced a reduction in systemic inflammation, and had negative sputum mycobacterial culture results.
Medical subject headings
- Anti-Bacterial Agents
- Clarithromycin
- Ethambutol
- Mycobacterium Infections, Nontuberculous
- Mycobacterium avium-intracellulare Infection
- Rifampin
- Tuberculosis, Pulmonary